Aegon Ltd. (AEG) Analyst/Investor Day Transcript
Aegon's new operating capital generation/FCF targets and capital return plans came in mid–high single digits below our expectations, with an SGUL deal and US redomicile costs heavier than anticipated. During the Q3 release, there was no change to guidance, with the €1.2 billion OCG reiteration. We lower our forecasts and target price to reflect the softer growth trajectory, but keep a Buy rating on AEG, remaining constructive on the long-term equity story.
Some of Britain's biggest savings and insurance groups are expected to take an early look at Aegon's UK business, which has been pushed into a strategic review as the Dutch group prepares to rebrand as Transamerica and shift its centre to the US. Panmure Liberum flags a broad field of potential bidders.
The insurer Aegon on Wednesday it's relocating its headquarters from the Netherlands to the U.S. and renaming itself Transamerica, as part of its ambition to become a leading U.S. life insurance and retirement company.
The Dutch insurer and asset manager plans to relocate its business to the U.S. and rebrand as Transamerica Inc.
Investors interested in Insurance - Multi line stocks are likely familiar with Aegon NV (AEG) and Prudential (PUK). But which of these two stocks offers value investors a better bang for their buck right now?
Here is how Aegon NV (AEG) and Bank of America (BAC) have performed compared to their sector so far this year.
Aegon (AEG) has transformed into a consistent performer, delivering strong results and a 6% dividend yield, with management meeting financial targets. AEG is relocating its domicile to the US, aiming to close the valuation gap with North American peers and potentially pursue M&A-driven growth. Management's track record and relationships suggest a possible merger or acquisition with Voya (VOYA), leveraging synergies and shared history.
Here is how Aegon NV (AEG) and American Healthcare REIT (AHR) have performed compared to their sector so far this year.
Aegon remains a Buy following strong H1 results, a €400 million share buyback, and the strategic sale of a.s.r. shares. The company's divestment of 12.5 million a.s.r. shares enhances financial flexibility, supports deleveraging, and creates room for shareholder returns. Potential US re-domicile and NYSE primary listing could drive a re-rating and higher liquidity for the company, with further details expected at the December Capital Market Day.
GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.
AEG, FMAO and FRME made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 2, 2025.